SOA 132

Drug Profile

SOA 132

Alternative Names: F 1322; SOA-132

Latest Information Update: 18 Jul 2007

Price : $50

At a glance

  • Originator UCB Japan
  • Developer Sosei
  • Class Antiasthmatics
  • Mechanism of Action 5-lipoxygenase inhibitors; Histamine receptor antagonists; Mast cell stabilisers; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Hypersensitivity

Most Recent Events

  • 18 Jul 2007 Discontinued - Preclinical for Asthma in Japan (Inhalation)
  • 18 Jul 2007 Discontinued - Preclinical for Allergy in Japan (Intranasal)
  • 15 Apr 2005 Preclinical trials in Allergy in Japan (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top